Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer

Despite effective strategies, resistance (R) in HER2+ breast cancer (BC) remains a challenge. While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Parental HER2+ BC cells...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Cancer Res
Main Authors: Sethunath, Vidyalakshmi, Hu, Huizhong, Angelis, Carmine De, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nicholas, Simon, Lukas M., Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L., Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C., Reis-Filho, Jorge S., Weigelt, Britta, Heiser, Laura M., Hilsenbeck, Susan G., Huang, Shixia, Rimawi, Mothaffar F., Gray, Joe W., Osborne, C. Kent, Schiff, Rachel
פורמט: Artigo
שפה:Inglês
יצא לאור: 2019
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825570/
https://ncbi.nlm.nih.gov/pubmed/31420371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-0756
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים